



WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off. : B-9 & 10, Laxmi Towers, L.S.C., Block C, Saraswati Vihar, Delhi -110034.

Phone : 27011428 Fax : 27023256

CIN No. L24232DL1996PLC227773

30.07.2018

THE BOMBAY STOCK EXCHANGE LIMITED

DEPARTMENT OF CORPORATE SERVICES

Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai – 400 001

File No: 524661

Dear Sirs

We wish to inform you that Board of Directors of the Company at its meeting held today has approved the Un-Audited Financial Statements (Standalone) for the quarter ended on June 30, 2018.

Pursuant to regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we enclose the Statement showing the Un-Audited Financial Results for the Quarter ended June 30, 2018 along with Limited Review Report.

Kindly acknowledge the receipt

For Welcure Drugs and Pharmaceuticals Limited

Rashi Goel

Company Secretary

V.P GUPTA & CO.

CHARTERED ACCOUNTANTS

288, GHALIB APPARTMENTS, PARWANA ROAD, PITAMPURA, DELHI-110034. PH.:27020321, 27029775, 9313675632
EMAIL-info@vpguptaandco.com

LIMITED REVIEW REPORT

Review Report to Welcure Drugs & Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of Welcure Drugs and Pharmaceuticals Limited for the period ended on 30.06.2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


For V.P. Gupta & Co.
Chartered Accountants

(FRNo. 000699N)

V.P. Gupta
Partner

M.No. 080577

Date: 30.07.2018





WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off. : B-9 & 10, Laxmi Towers, L.S.C., Block C, Saraswati Vihar, Delhi -110034.

Phone : 27011428 Fax : 27023256

CIN No. L24232DL1996PLC227773

30.07.2018

THE STOCK EXCHANGE MUMBAI
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

File No: 524661

Sub: Regulation 33 of the SEBI Listing Regulations

Dear Sir,

We are hereunder furnishing the un-audited financial results for the quarter ended 30.06.18 as reviewed by the Audit Committee & approved by Board of Directors in their respective meetings held on 30.07.2018.

(Figures in Lacs)

Particulars	Figures as at end of current reporting period 30.06.2018(un-audited)	Figures as at end of previous reporting period 30.06.2017(un-audited)
I. Revenue from Operations		
(a) Net Sales/ Income from operations(net of excise duty)	-	-
(b) Other Operating Income	4.00	5.28
II. Other Income	-	-
III. Total Revenue (I+ II)	4.00	5.28
IV. Expenses		
(a)Cost of Raw Material Consumed	-	-
(b)Purchase of Stock in trade	-	-
(c)Changes in inventories of finished goods, work-in-progress and stock in trade	-	-
(d)Employee benefit expenses	-	-
(e) Finance Cost	-	-
(e) Depreciation and amortization expense	-	-
(f) Other expenses	3.93	4.93
Total Expenses	3.93	4.93
V. Profit/(Loss) from Operations before Exceptional items and tax Items III-IV)	0.07	0.35
VI. Exceptional Items	-	-
VII. Profit Before Tax (V-VII)	0.07	0.35
VIII. Tax Expense		
(1) Current tax	-	-
(2) Deferred Tax	-	-
IX. Profit(Loss) for the period from continuing operations(VII-VIII)	0.07	0.35
X. Profit(Loss) from discontinuing operations	-	-
XI. Tax expense of discontinuing operations	-	-
XII. Profit(Loss) from discontinuing operations (after tax) (X-XI)	-	-
XIII. Profit(loss) for the period(IX+XII)	0.07	0.35
XIV. Other Comprehensive Income/(Loss)	-	-
XV.Total Comprehensive Income/(Loss)(XIII+XIV)	0.07	0.35
XVI. Earnings per equity share:		
(3) Basic	-	-
(4) Diluted	-	-

Note:

1. The above un-audited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 30, 2018.
2. The financial statement of the Company have been prepared in accordance with Indian Accounting Standard (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to section 133 of the Companies Act, 2013 read with relevant rules.

Thanking you,
for **Welcure Drugs & Pharmaceuticals Ltd.**


Sudhir Chandra
Managing Director


M.L. Bhateja
Director & CFO